FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1502126985> ?p ?o ?g. }

• W1502126985 endingPage "97" @default.
• W1502126985 startingPage "89" @default.
• W1502126985 abstract "Purpose: To evaluate the efficacy and tolerability of adjunctive brivaracetam (BRV), a novel high-affinity synaptic vesicle protein 2A ligand that also displays inhibitory activity at neuronal voltage-dependent sodium channels, in adult epilepsy patients with uncontrolled partial-onset seizures. Methods: A phase IIb, double-blind, randomized, placebo-controlled, parallel-group, dose-ranging study (N01114; NCT00175929) was conducted in patients aged 16–65 years. To be included in the study, patients were required to have experienced four or more partial-onset seizures during a 4-week prospective baseline, despite treatment with 1–2 concomitant antiepileptic drugs. Patients were randomized in a ratio of 1:1:1 to receive BRV 50 mg/day (BRV50), 150 mg/day (BRV150), or placebo. A 3-week up-titration period was followed by a 7-week maintenance period (total treatment period of 10 weeks). Key Findings: A total of 157 patients were randomized (intent-to-treat [ITT] population; BRV50 n = 53, BRV150 n = 52, placebo n = 52) and overall 148 (94.3%) completed the study. The percent reduction in baseline-adjusted partial-onset seizure frequency/week over placebo during the 7-week maintenance period (primary efficacy outcome) did not reach statistical significance (14.7% for BRV50 [p = 0.093] and 13.6% for BRV150 [p = 0.124]). However, during the entire 10-week treatment period a statistically significant difference was observed for both BRV groups (17.7% for BRV50 [p = 0.026] and 16.3% for BRV150 [p = 0.043]). The median percent reduction from baseline in partial-onset seizure frequency/week during the maintenance period was 38.2% for BRV50 (p = 0.017) and 30.0% for BRV150 (p = 0.113) versus 18.9% in the placebo group. During the treatment period, this was 34.9% for BRV50 (p = 0.004) and 28.3% for BRV150 (p = 0.070) compared with 16.3% for placebo. Fifty percent responder rates during the maintenance period were 23.1% for placebo compared with 39.6% for BRV50 (odds ratio [OR] 2.17, p = 0.077) and 33.3% for BRV150 (OR 1.66, p = 0.261). During the treatment period, 50% responder rates were 17.3% for placebo compared with 35.8% for BRV50 (OR 2.69, p = 0.038) and 30.8% for BRV150 (OR 2.15, p = 0.114). Nine patients were free from partial-onset seizures during the 10-week treatment period (five patients [9.4%] in the BRV50 group and three [5.8%] in the BRV150 group compared with one patient [1.9%] in the placebo group). Treatment-emergent adverse events (TEAEs) reported during the treatment period were mostly mild-to-moderate with similar incidence across treatment groups (BRV50 36/53, 67.9%; BRV150 35/52, 67.3%; placebo 37/52, 71.2%). The most frequently reported TEAEs in BRV groups were headache, fatigue, nasopharyngitis, nausea, somnolence, and dizziness, although nausea had a higher incidence in the placebo group. Significance: In this double-blind, placebo-controlled, phase IIb study of adjunctive BRV (50 and 150 mg/day) in adults with uncontrolled partial-onset seizures, the primary efficacy analysis did not reach statistical significance; however, statistically significant differences compared with placebo were observed on several secondary efficacy outcomes. BRV was well tolerated." @default.
• W1502126985 created "2016-06-24" @default.
• W1502126985 creator A5016784917 @default.
• W1502126985 creator A5025460752 @default.
• W1502126985 creator A5032020329 @default.
• W1502126985 creator A5059287667 @default.
• W1502126985 creator A5088572719 @default.
• W1502126985 date "2012-07-19" @default.
• W1502126985 modified "2023-09-24" @default.
• W1502126985 title "Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial-onset seizures: A phase IIb, randomized, controlled trial" @default.
• W1502126985 cites W1576738253 @default.
• W1502126985 cites W2004177049 @default.
• W1502126985 cites W2037616672 @default.
• W1502126985 cites W2055249621 @default.
• W1502126985 cites W2061209838 @default.
• W1502126985 cites W2063476303 @default.
• W1502126985 cites W2066303030 @default.
• W1502126985 cites W2077659055 @default.
• W1502126985 cites W2095271866 @default.
• W1502126985 cites W2107427879 @default.
• W1502126985 cites W2117025783 @default.
• W1502126985 cites W2120228951 @default.
• W1502126985 cites W2134247911 @default.
• W1502126985 cites W2582757403 @default.
• W1502126985 cites W4206572492 @default.
• W1502126985 cites W4239594659 @default.
• W1502126985 cites W4247796277 @default.
• W1502126985 doi "https://doi.org/10.1111/j.1528-1167.2012.03598.x" @default.
• W1502126985 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22813235" @default.
• W1502126985 hasPublicationYear "2012" @default.
• W1502126985 type Work @default.
• W1502126985 sameAs 1502126985 @default.
• W1502126985 citedByCount "115" @default.
• W1502126985 countsByYear W15021269852012 @default.
• W1502126985 countsByYear W15021269852013 @default.
• W1502126985 countsByYear W15021269852014 @default.
• W1502126985 countsByYear W15021269852015 @default.
• W1502126985 countsByYear W15021269852016 @default.
• W1502126985 countsByYear W15021269852017 @default.
• W1502126985 countsByYear W15021269852018 @default.
• W1502126985 countsByYear W15021269852019 @default.
• W1502126985 countsByYear W15021269852020 @default.
• W1502126985 countsByYear W15021269852021 @default.
• W1502126985 countsByYear W15021269852022 @default.
• W1502126985 countsByYear W15021269852023 @default.
• W1502126985 crossrefType "journal-article" @default.
• W1502126985 hasAuthorship W1502126985A5016784917 @default.
• W1502126985 hasAuthorship W1502126985A5025460752 @default.
• W1502126985 hasAuthorship W1502126985A5032020329 @default.
• W1502126985 hasAuthorship W1502126985A5059287667 @default.
• W1502126985 hasAuthorship W1502126985A5088572719 @default.
• W1502126985 hasBestOaLocation W15021269851 @default.
• W1502126985 hasConcept C118552586 @default.
• W1502126985 hasConcept C126322002 @default.
• W1502126985 hasConcept C142724271 @default.
• W1502126985 hasConcept C168563851 @default.
• W1502126985 hasConcept C197934379 @default.
• W1502126985 hasConcept C204787440 @default.
• W1502126985 hasConcept C27081682 @default.
• W1502126985 hasConcept C2778186239 @default.
• W1502126985 hasConcept C2778375690 @default.
• W1502126985 hasConcept C2779384505 @default.
• W1502126985 hasConcept C2908647359 @default.
• W1502126985 hasConcept C3018162438 @default.
• W1502126985 hasConcept C42219234 @default.
• W1502126985 hasConcept C71924100 @default.
• W1502126985 hasConcept C99454951 @default.
• W1502126985 hasConceptScore W1502126985C118552586 @default.
• W1502126985 hasConceptScore W1502126985C126322002 @default.
• W1502126985 hasConceptScore W1502126985C142724271 @default.
• W1502126985 hasConceptScore W1502126985C168563851 @default.
• W1502126985 hasConceptScore W1502126985C197934379 @default.
• W1502126985 hasConceptScore W1502126985C204787440 @default.
• W1502126985 hasConceptScore W1502126985C27081682 @default.
• W1502126985 hasConceptScore W1502126985C2778186239 @default.
• W1502126985 hasConceptScore W1502126985C2778375690 @default.
• W1502126985 hasConceptScore W1502126985C2779384505 @default.
• W1502126985 hasConceptScore W1502126985C2908647359 @default.
• W1502126985 hasConceptScore W1502126985C3018162438 @default.
• W1502126985 hasConceptScore W1502126985C42219234 @default.
• W1502126985 hasConceptScore W1502126985C71924100 @default.
• W1502126985 hasConceptScore W1502126985C99454951 @default.
• W1502126985 hasIssue "1" @default.
• W1502126985 hasLocation W15021269851 @default.
• W1502126985 hasLocation W15021269852 @default.
• W1502126985 hasOpenAccess W1502126985 @default.
• W1502126985 hasPrimaryLocation W15021269851 @default.
• W1502126985 hasRelatedWork W1995302457 @default.
• W1502126985 hasRelatedWork W2092776389 @default.
• W1502126985 hasRelatedWork W2132146185 @default.
• W1502126985 hasRelatedWork W2144323667 @default.
• W1502126985 hasRelatedWork W2518276265 @default.
• W1502126985 hasRelatedWork W2971064972 @default.
• W1502126985 hasRelatedWork W2999631457 @default.
• W1502126985 hasRelatedWork W4281723283 @default.
• W1502126985 hasRelatedWork W4295088939 @default.
• W1502126985 hasRelatedWork W4317535666 @default.
• W1502126985 hasVolume "54" @default.

• next